Printer Friendly

Aquinox Pharmaceuticals completes patient enrolment in Phase II KINSHIP trial of AQX-1125.

M2 PHARMA-May 6, 2015-Aquinox Pharmaceuticals completes patient enrolment in Phase II KINSHIP trial of AQX-1125

(C)2015 M2 COMMUNICATIONS

Canada-based Aquinox Pharmaceuticals has completed patient enrolment in the Phase II KINSHIP trial of its lead drug candidate, AQX-1125, it was reported on Tuesday.

The product is intended to treat atopic dermatitis and is a small molecule activator of SHIP1 suitable for oral, once daily dosing, which has been assessed in multiple preclinical studies and clinical trials.

The randomised, double-blind, multicentre, placebo-controlled KINSHIP trial is being conducted at sites in Canada to evaluate the efficacy and safety of AQX-1125 in around 50 adult patients with mild to moderate atopic dermatitis, as a proof-of-concept trial in this indication.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 6, 2015
Words:127
Previous Article:China Food and Drug Administration grants approval to Bayer's Xarelto.
Next Article:Bactiguard signs agreement for distribution in Israel.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters